Journal of orthopaedic surgery and research · 2025
miR-29c-3p downregulation accelerates spinal cord injury progression by targeting BRD4.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Dawei, Wang Xiaona, Wu Yingshuang, Qi Sina, Hu Haifeng, Guo Jifei, Luo Yi
Аннотация
BACKGROUND: Spinal cord injury (SCI) can cause severe motor and sensory deficits below the injury site. Studies have highlighted the multifaceted regulatory roles of miR-29c-3p in neuronal development and function; however, its role in SCI remains unclear.
METHODS: In this research 105 healthy controls and 159 patients with SCI were recruited. The miR-29c-3p and BRD4 levels in serum or cells were estimated by RT-qPCR. The diagnostic performance of miR-29c-3p was assessed by ROC curve. Moreover, cell viability and apoptosis were measured via CCK8 and flow cytometry. The pro-inflammatory cytokines were examined by ELISA assay. The pathological condition of SCI was modeled with LPS-induced PC12 cells. The target relationship between miR-29c-3p and BRD4 was verified by the dual-luciferase reporter assay.
RESULTS: Serum miR-29c-3p was remarkedly decreased in the SCI population and showed high clinical diagnostic performance. Under pathological conditions, the upregulation of miR-29c-3p effectively reversed the significant reduction in cell viability and the increase in apoptosis rate. Moreover, enhanced pro-inflammatory cytokines including TNF-α, IL-6 and IL-1β were also attenuated by the upregulation of miR-29c-3p. BRD4 was identified as a target of miR-29c-3p and negatively regulated by miR-29c-3p.
CONCLUSIONS: A decrease in miR-29c-3p is a promising diagnostic indicator for SCI, and downregulation of miR-29c-3p accelerates the progression of SCI by targeting BRD4.
METHODS: In this research 105 healthy controls and 159 patients with SCI were recruited. The miR-29c-3p and BRD4 levels in serum or cells were estimated by RT-qPCR. The diagnostic performance of miR-29c-3p was assessed by ROC curve. Moreover, cell viability and apoptosis were measured via CCK8 and flow cytometry. The pro-inflammatory cytokines were examined by ELISA assay. The pathological condition of SCI was modeled with LPS-induced PC12 cells. The target relationship between miR-29c-3p and BRD4 was verified by the dual-luciferase reporter assay.
RESULTS: Serum miR-29c-3p was remarkedly decreased in the SCI population and showed high clinical diagnostic performance. Under pathological conditions, the upregulation of miR-29c-3p effectively reversed the significant reduction in cell viability and the increase in apoptosis rate. Moreover, enhanced pro-inflammatory cytokines including TNF-α, IL-6 and IL-1β were also attenuated by the upregulation of miR-29c-3p. BRD4 was identified as a target of miR-29c-3p and negatively regulated by miR-29c-3p.
CONCLUSIONS: A decrease in miR-29c-3p is a promising diagnostic indicator for SCI, and downregulation of miR-29c-3p accelerates the progression of SCI by targeting BRD4.